Streptomyces Fradiae Patents (Class 435/896)
  • Patent number: 6670505
    Abstract: A process for recovering a desired organic acid from a solution includes the steps of: providing an aqueous solution including at least one desired organic acid or its acid anion; adjusting the proton concentration in the aqueous solution to a desired level, with the desired proton concentration being selected, at least in part, by the amount of available protons needed to associate with the acid anions of the desired organic acid(s) to be recovered and/or acid anions that are weaker than the desired organic acids; and recovering at least a portion of the at least one desired organic acid from the aqueous phase. The desired proton concentration can be based on the amount of available protons being greater than, less than or substantially equal, to the amount of protons needed to associate with the anion of the desired organic acid(s) and acid anions that are weaker than the desired organic acid(s).
    Type: Grant
    Filed: March 7, 2000
    Date of Patent: December 30, 2003
    Assignee: Eastman Chemical Company
    Inventors: Nick Allen Collins, Mark Robert Shelton, George William Tindall, Steven Thomas Perri, Ruairi Seosamh O'Meadhra, Chester Wayne Sink, Bhaskar Krishna Arumugam, John Clark Hubbs
  • Patent number: 5698420
    Abstract: Preparation of 4'-deoxy-O-mycaminosyltylonolide by feeding repromicin to a fermentation broth of a strain of the microorganism Streptomyces fradiae (ATCC 31733) under aerobic conditions in an aqueous nutrient medium containing inorganic salts and assimilable sources of carbon and nitrogen.
    Type: Grant
    Filed: November 26, 1996
    Date of Patent: December 16, 1997
    Assignee: Pfizer Inc.
    Inventor: Lapyuen H. Lam
  • Patent number: 5665586
    Abstract: According to the present invention, a novel protease derived from Streptomyces fradiae for cleaving the C-terminal of a glutamic acid residue in an amino acid sequence of a polypeptide and a production method for this protease from Streptomyces fradiae are provided, and the characteristics of this protease are made clear. Further, DNA sequences for encoding this protease and a prepropeptide are also made clear. The protease specific to glutamic acid can be used for a variety of purposes including analysis of a protein and cleavage of a peptide chain at a desired site in a fusion protein.
    Type: Grant
    Filed: November 18, 1994
    Date of Patent: September 9, 1997
    Assignee: Shionogi & Co., Ltd.
    Inventors: Etsuo Nakamura, Hiroshige Tsuzuki, Kengo Kitadokoro, Masaru Shin, Hiroshi Teraoka
  • Patent number: 5047240
    Abstract: Method for producing a proteolytic complex formed after cultivation of a strain of Streptomyces fradiae while maintaining the pH of the culture medium between 7 and 7.5, and extracting said complex by filtration in the presence of a clarifying agent and ultrafiltration on a specific membrane and finally atomization; the invention also relates to the new proteolytic complex thus obtained and its applications in zootechny due to its stimulating effect on the activity of the pancreas.
    Type: Grant
    Filed: April 18, 1988
    Date of Patent: September 10, 1991
    Inventor: Michel Hooreman
  • Patent number: 4994270
    Abstract: New peptide antibiotic A54145, individual A54145 components A, A.sub.1, B, B.sub.1, C, D, E and F and their pharmaceutically acceptable salts, are useful antibacterial agents which also improve growth performance in animals, especially poultry. Biologically pure cultures of the A54145-producing Streptomyces fradiae cultures NRRL 18158, NRRL 18159 and NRRL 18160 cultures and methods of making antibiotic A54145 using those cultures are also provided.
    Type: Grant
    Filed: April 11, 1988
    Date of Patent: February 19, 1991
    Assignee: Eli Lilly and Company
    Inventors: LaVerne D. Boeck, David S. Fukuda, Jon S. Mynderse, Marvin M. Hoehn, Ralph E. Kastner, Harold R. Papiska
  • Patent number: 4977083
    Abstract: Improved processes for preparing A54145 components and cyclic peptide derivatives (A54145 compounds) comprising: (1) feeding alkanoic or alkenoic acids or alcohols, or esters or salts thereof, (2) feeding glucose at a rate from about 6-9 g/L/day, or (3) feeding enzymatic soy digest at a rate from about 2-4 g/L/day to an A54145-producing culture during its fermentation and recovering the A54145 compound, are provided.
    Type: Grant
    Filed: April 11, 1988
    Date of Patent: December 11, 1990
    Assignee: Eli Lilly and Company
    Inventor: LaVerne D. Boeck
  • Patent number: 4939125
    Abstract: The O-acyl derivatives of urdamycin A exhibit an antibiotic or antitumoral activity.
    Type: Grant
    Filed: October 5, 1987
    Date of Patent: July 3, 1990
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Axel Zeeck, Thomas Ciesiolka, Hans Zahner, Hannelore Drautz
  • Patent number: 4889809
    Abstract: The tlrC gene is a novel tylosin resistance-conferring gene isolated from Streptomyces fradiae and used to construct a number of cloning vectors for use in Streptomyces. One such cloning vector, plasmid pSKC10, can be obtained in S. fradiae JS87 under the accession number NRRL 18072. S. fradiae JS87 is the preferred host when the tlrC gene is used to select tylosin-resistant Streptomyces transformants.
    Type: Grant
    Filed: July 25, 1986
    Date of Patent: December 26, 1989
    Assignee: Eli Lilly and Company
    Inventors: Virginia A. Birmingham, Karen L. Cox, Eugene T. Seno
  • Patent number: 4859655
    Abstract: A new substance, urdamycin G, has been found which, like its O-acyl derivatives, exhibits an antibiotic or antitumoral activity.
    Type: Grant
    Filed: August 26, 1987
    Date of Patent: August 22, 1989
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Axel Zeeck, Thomas Ciesiolka, Jurgen Rohr, Hans Zahner, Hannelore Drautz
  • Patent number: 4843002
    Abstract: A novel method of selecting Streptomyces recombinant DNA-containing host cells and vectors useful in exemplifying the method are described. The vectors confer apramycin resistance to sensitive Streptomyces host cells and thus provide a convenient method of selecting Streptomyces transformants. The apramycin resistance-conferring gene used in the method is an acetyltransferase aac(3)IV gene and can be isolated from E. coli K12 BE1041/pKC309 (NRRL B-15827) on an .about.1.5 kb PstI-EcoRI restriction fragment.
    Type: Grant
    Filed: September 27, 1984
    Date of Patent: June 27, 1989
    Assignee: Eli Lilly and Company
    Inventors: R. Nagaraja Rao, Richard K. Stanzak
  • Patent number: 4766066
    Abstract: The invention relates to a method and cloning vehicle for the expression of a functional polypeptide in Streptomyces. A recombinant DNA cloning vehicle was genetically engineered to bring the expression of the neomycin phosphotransferase gene under the control of the Escherichia coli bacteriophage .lambda.p.sub.L promoter.
    Type: Grant
    Filed: September 27, 1984
    Date of Patent: August 23, 1988
    Assignee: Eli Lilly and Company
    Inventors: Stuart A. Kuhstoss, R. Nagaraja Rao
  • Patent number: 4753886
    Abstract: The present invention discloses selectable, recombinant DNA shuttle vectors for use in streptomycetes and E. coli. The shuttle vectors of the present invention are present at moderately high copy number. The invention further discloses transformants of the aforementioned vectors.
    Type: Grant
    Filed: August 10, 1984
    Date of Patent: June 28, 1988
    Assignee: Eli Lilly and Company
    Inventors: Charles L. Hershberger, Jeffrey L. Larson
  • Patent number: 4745056
    Abstract: Cloning vectors are disclosed to obtain secretion of a desired protein from a host Streptomyces when a structural gene coding for the protein is inserted into the vector. The vector has: (1) regulatory DNA that includes a promoter sequence effective to start transcription in the host Streptomyces and DNA that encodes a ribosome-binding site; (2) a DNA sequence that codes for a signal sequence that occurs naturally in a Streptomyces strain or that derives from such a DNA sequence; and (3) at least one engineered restriction endonuclease recognition site positioned for the insertion of a structural gene, the DNA that encodes a signal sequence and attached structural gene being transcribed and translated together under the control of the regulatory DNA. Expression vectors are disclosed which include a structural gene coding for a desired protein so positioned. Streptomyces cells containing the vector and methods of using them to produce the desired protein are disclosed.
    Type: Grant
    Filed: October 23, 1984
    Date of Patent: May 17, 1988
    Assignee: Biotechnica International, Inc.
    Inventors: Sonia Guterman, Janice Pero, Phillips Robbins
  • Patent number: 4698307
    Abstract: The present invention disclosed novel recombinant DNA cloning vectors including pMND1000 and vectors derived therefrom for use in Streptomyces and related organisms. These novel cloning vectors contain genetic markers that provide antibiotic resistance or colorimetric selectivity to the host cells. The invention further comprises transformants of the aforementioned vectors.
    Type: Grant
    Filed: August 10, 1984
    Date of Patent: October 6, 1987
    Assignee: Eli Lilly and Company
    Inventors: James A. Mabe, Walter M. Nakatsukasa
  • Patent number: 4683206
    Abstract: The present invention disclosed novel recombinant DNA cloning vectors for use in Streptomyces and related organisms. These novel cloning vectors contain genetic markers that provide antibiotic resistance or colorimetric selectivity to the host cells. The invention further comprises transformants of the aforementioned vectors.
    Type: Grant
    Filed: August 10, 1984
    Date of Patent: July 28, 1987
    Assignee: Eli Lilly and Company
    Inventors: James A. Mabe, Walter M. Nakatsukasa
  • Patent number: 4468462
    Abstract: The present invention discloses selectable recombinant DNA cloning vectors for use in Streptomyces.
    Type: Grant
    Filed: December 22, 1982
    Date of Patent: August 28, 1984
    Assignee: Eli Lilly and Company
    Inventors: Nancy E. Malin, Jeffrey T. Fayerman, Michael D. Jones, James A. Mabe, Walter M. Nakatsukasa
  • Patent number: 4460691
    Abstract: A novel plasmid cloning vector, designated pUC13, can be used, advantageously, in recombinant DNA work. This plasmid has been identified as a prophage. The procedures used to recognize this prophage can be used to recognize other prophages in Streptomyces.
    Type: Grant
    Filed: August 10, 1981
    Date of Patent: July 17, 1984
    Assignee: The Upjohn Company
    Inventor: Shiau-Ta Chung
  • Patent number: 4440857
    Abstract: A new microorganism, Streptomyces fradiae NRRL 12201, which produces mycarosyltylactone (5-O-mycarosyl-20-dihydro-20,23-dideoxytylonolide) and a process for preparing tylactone (20-dihydro-20,23-dideoxytylonolide) and mycarosyltylactone by submerged aerobic fermentation of this microorganism, or a mycarosyltylactone-producing mutant or recombinant thereof, are provided.
    Type: Grant
    Filed: March 18, 1982
    Date of Patent: April 3, 1984
    Assignee: Eli Lilly and Company
    Inventors: Eugene T. Seno, Richard H. Baltz
  • Patent number: 4438197
    Abstract: The antibacterial compound DC-38-V is produced by culturing a microorganism belonging to the genus Streptomyces.
    Type: Grant
    Filed: April 16, 1982
    Date of Patent: March 20, 1984
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Fusao Tomita, Yuzuru Matsuda, Kunikatsu Shirahata, Keiichi Takahashi, Hirofumi Nakano, Tomoyasu Sato, Shuji Okubo, Nobuo Nakamura
  • Patent number: 4423148
    Abstract: 20-Dihydro-20-deoxy-23-de(mycinosyloxy)tylosin (20-deoxo-DMOT), specified 2'-acyl ester derivatives, and their acid addition salts are useful intermediates and antibacterial agents. Methods of preparing 20-deoxo-DMOT and 5-O-mycaminosyltylactone by fermentation of Streptomyces fradiae ATCC 31733 are included.
    Type: Grant
    Filed: July 2, 1982
    Date of Patent: December 27, 1983
    Assignee: Eli Lilly and Company
    Inventor: Gene M. Wild
  • Patent number: 4419447
    Abstract: 23-Demycinosyltylosin (DMT) which has the formula: ##STR1## 20-dihydro-DMT, specified acyl ester derivatives, and their acid addition salts are useful antibacterial agents. Improved methods of making 5-O-mycaminosyltylonolide (OMT) and 20-dihydro-OMT by mild acid hydrolysis of DMT and 20-dihydro-DMT, respectively, are included.
    Type: Grant
    Filed: May 6, 1981
    Date of Patent: December 6, 1983
    Assignee: Eli Lilly and Company
    Inventors: Richard H. Baltz, Gene M. Wild, Eugene T. Seno
  • Patent number: 4400465
    Abstract: A process for preparing a B30-threonine-insulin which comprising reacting a des-B30-insulin with an excess amount of threonine derivative in the presence of an enzyme specifically acting on the basic-amino-acid carbonyl in peptide bondings.
    Type: Grant
    Filed: December 31, 1981
    Date of Patent: August 23, 1983
    Assignee: Shionogi & Co., Ltd.
    Inventors: Kazuyuki Morihara, Tatsushi Oka, Hiroshige Tsuzuki
  • Patent number: 4385116
    Abstract: 2'"-O-demethylmacrocin (DOMM) which has the formula: ##STR1## 20-dihydro-DOMM, 2'"-O-demethyllactenocin (DOML), 20-dihydro-DOML, specified acyl ester derivatives, and their acid addition salts are useful antibacterial agents.
    Type: Grant
    Filed: July 15, 1980
    Date of Patent: May 24, 1983
    Assignee: Eli Lilly and Company
    Inventors: Richard H. Baltz, Gene M. Wild, Eugene T. Seno
  • Patent number: 4376823
    Abstract: A method of increasing the yield of a desired product, such as an antibiotic, by an organism which normally must first become inducibly resistant to that product before it can produce the product in maximum yields comprises producing constitutively resistant cells of the organism by supplementing a culture of the organism with an agent in which only cells able to specifically modify the 23S ribosomal RNA constitutively, rather than inducibly, survive thereby producing an organism in which the resistance to the product is expressed without the need for activation by the induction process; followed by purification and utilization of that organism for increased product production.
    Type: Grant
    Filed: June 18, 1981
    Date of Patent: March 15, 1983
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Bernard Weisblum
  • Patent number: 4366247
    Abstract: A process for preparing tylactone (20-dihydro-20,23-dideoxytylonolide), which has the formula: ##STR1## by submerged aerobic fermentation of Streptomyces fradiae NRRL 12188 or a tylactone-producing mutant or recombinant thereof is provided.
    Type: Grant
    Filed: July 2, 1980
    Date of Patent: December 28, 1982
    Assignee: Eli Lilly and Company
    Inventors: Richard H. Baltz, Eugene T. Seno
  • Patent number: 4334019
    Abstract: 23-De(mycinosyloxy)tylosin (DMOT) which has the formula: ##STR1## 20-dihydro-DMOT, specified acyl ester derivatives, and the acid addition salts thereof are useful antibacterial agents. New methods of making 23-deoxy-5-O-mycaminosyltylonolide (DOMT) and 20-dihydro-DOMT by mild acid hydrolysis of DMOT and 20-dihydro-DMOT, respectively, are included.
    Type: Grant
    Filed: May 8, 1981
    Date of Patent: June 8, 1982
    Assignee: Eli Lilly and Company
    Inventors: Richard H. Baltz, Gene M. Wild, Eugene T. Seno
  • Patent number: 4320196
    Abstract: A process for preparing a B30-threonine-insulin which comprising reacting a des-B30-insulin with an excess amount of threonine derivative in the presence of an enzyme specifically acting on the basic-amino-acid carbonyl in peptide bondings.
    Type: Grant
    Filed: April 9, 1980
    Date of Patent: March 16, 1982
    Assignee: Shionogi & Co., Ltd.
    Inventors: Kazuyuki Morihara, Tatsushi Oka, Hiroshige Tsuzuki
  • Patent number: 4304856
    Abstract: 20-Dihydro-20-deoxy-23-demycinosyltylosin (DH-DO-DMT), 20-dihydro-20-deoxy-5-O-mycaminosyltylonolide (DH-DO-OMT), specified acyl ester derivatives, and their acid addition salts are useful intermediates and antibacterial agents. Methods of preparing DH-DO-DMT and DH-DO-OMT by fermentation of Streptomyces fradiae and the microorganism S. fradiae ATCC 31733 are included.
    Type: Grant
    Filed: November 10, 1980
    Date of Patent: December 8, 1981
    Assignee: Eli Lilly and Company
    Inventors: Richard H. Baltz, Herbert A. Kirst, Gene M. Wild, Eugene T. Seno
  • Patent number: 4212941
    Abstract: 9-(2-O-Acyl-.beta.-D-arabinofuranosyl)adenine compounds and their production by enzymatic removal of the 3-O-acyl and 5-O-acyl groups of a 9-(2,3-di-O-acyl-.beta.-D-arabinofuranosyl)adenine compound or a 9-(2,3,5-tri-O-acyl-.beta.-D-arabinofuranosyl)adenine compound. The monoester compounds are useful as antiviral agents. The compounds are water-soluble and lipophilic, thereby being adaptable to a wide variety of pharmaceutical formulations.
    Type: Grant
    Filed: May 23, 1977
    Date of Patent: July 15, 1980
    Assignee: Warner-Lambert Company
    Inventor: David C. Baker
  • Patent number: 4170643
    Abstract: Novel aminoglycoside-aminocyclitol derivatives corresponding to the general formula: ##STR1## wherein R.sub.1 and R.sub.2, which are different, represent hydrogen or CH.sub.2 NH.sub.2 and R is selected from the group consisting of: ##STR2## wherein R.sub.3 represents NH.sub.2 or OH and R.sub.4 represents ##STR3## wherein R.sub.5 represents hydrogen or methyl and the pharmaceutically acceptable acid addition salts thereof.They are useful as antibiotics.
    Type: Grant
    Filed: April 13, 1977
    Date of Patent: October 9, 1979
    Assignee: Labaz
    Inventors: Stephan Gero, Daniel Mercier, Alain Olesker, Andre Cier